 Christine Walsh
Concepts (183)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Ovarian Neoplasms | 18 | 2023 | 416 | 4.620 |
Why?
| | Endometrial Neoplasms | 7 | 2022 | 153 | 2.050 |
Why?
| | Adenocarcinoma, Clear Cell | 3 | 2016 | 14 | 1.170 |
Why?
| | BRCA2 Protein | 3 | 2021 | 44 | 1.020 |
Why?
| | Neoplasms, Glandular and Epithelial | 5 | 2017 | 40 | 0.970 |
Why?
| | BRCA1 Protein | 2 | 2015 | 57 | 0.820 |
Why?
| | Myeloproliferative Disorders | 1 | 2021 | 25 | 0.800 |
Why?
| | Cystadenocarcinoma, Serous | 5 | 2016 | 48 | 0.780 |
Why?
| | Maintenance Chemotherapy | 1 | 2020 | 22 | 0.760 |
Why?
| | Poly(ADP-ribose) Polymerase Inhibitors | 2 | 2021 | 75 | 0.750 |
Why?
| | Indazoles | 1 | 2020 | 59 | 0.740 |
Why?
| | Deoxycytidine | 1 | 2021 | 136 | 0.730 |
Why?
| | Phthalazines | 1 | 2020 | 43 | 0.730 |
Why?
| | Bevacizumab | 1 | 2020 | 119 | 0.730 |
Why?
| | Neoplasm Staging | 8 | 2021 | 1207 | 0.700 |
Why?
| | Cisplatin | 1 | 2021 | 272 | 0.700 |
Why?
| | Piperidines | 1 | 2020 | 168 | 0.680 |
Why?
| | Medical Oncology | 2 | 2020 | 231 | 0.680 |
Why?
| | Tumor Suppressor Protein p53 | 1 | 2022 | 450 | 0.650 |
Why?
| | Piperazines | 1 | 2020 | 314 | 0.630 |
Why?
| | Gynecology | 1 | 2020 | 185 | 0.600 |
Why?
| | Fellowships and Scholarships | 1 | 2020 | 244 | 0.600 |
Why?
| | Thromboplastin | 1 | 2017 | 65 | 0.580 |
Why?
| | Neoplasm Recurrence, Local | 8 | 2021 | 878 | 0.570 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2021 | 667 | 0.570 |
Why?
| | Colorectal Neoplasms, Hereditary Nonpolyposis | 2 | 2023 | 31 | 0.560 |
Why?
| | Genetic Testing | 2 | 2017 | 384 | 0.540 |
Why?
| | Genital Neoplasms, Female | 2 | 2015 | 73 | 0.530 |
Why?
| | Venous Thrombosis | 1 | 2017 | 145 | 0.510 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 2 | 2021 | 1374 | 0.490 |
Why?
| | Cystadenocarcinoma, Papillary | 2 | 2008 | 5 | 0.400 |
Why?
| | Adenocarcinoma, Papillary | 1 | 2011 | 9 | 0.400 |
Why?
| | Biomarkers, Tumor | 2 | 2022 | 1053 | 0.390 |
Why?
| | Genes, BRCA2 | 3 | 2023 | 25 | 0.390 |
Why?
| | Genes, BRCA1 | 3 | 2023 | 31 | 0.380 |
Why?
| | Polymorphism, Single Nucleotide | 4 | 2014 | 2038 | 0.380 |
Why?
| | Ovariectomy | 4 | 2023 | 122 | 0.380 |
Why?
| | Female | 31 | 2023 | 60635 | 0.380 |
Why?
| | Aged, 80 and over | 13 | 2021 | 6454 | 0.380 |
Why?
| | Internship and Residency | 1 | 2020 | 964 | 0.380 |
Why?
| | Carcinoma, Endometrioid | 1 | 2010 | 47 | 0.370 |
Why?
| | Venous Thromboembolism | 1 | 2013 | 235 | 0.350 |
Why?
| | Aged | 18 | 2021 | 19359 | 0.350 |
Why?
| | DNA Repair | 1 | 2011 | 197 | 0.350 |
Why?
| | Middle Aged | 20 | 2021 | 27173 | 0.350 |
Why?
| | Platinum | 2 | 2021 | 40 | 0.330 |
Why?
| | Survival Rate | 5 | 2021 | 1679 | 0.330 |
Why?
| | Uniparental Disomy | 1 | 2008 | 7 | 0.330 |
Why?
| | Loss of Heterozygosity | 1 | 2008 | 40 | 0.330 |
Why?
| | Homologous Recombination | 2 | 2020 | 22 | 0.310 |
Why?
| | Neoplasms | 1 | 2021 | 2147 | 0.300 |
Why?
| | CA-125 Antigen | 2 | 2021 | 13 | 0.290 |
Why?
| | Humans | 32 | 2023 | 117052 | 0.280 |
Why?
| | Antineoplastic Agents | 1 | 2017 | 1941 | 0.280 |
Why?
| | Proto-Oncogene Proteins c-mdm2 | 1 | 2006 | 56 | 0.280 |
Why?
| | Prognosis | 5 | 2022 | 3390 | 0.260 |
Why?
| | Neoplasms, Multiple Primary | 1 | 2005 | 53 | 0.250 |
Why?
| | Adult | 18 | 2021 | 31003 | 0.240 |
Why?
| | DNA-Binding Proteins | 1 | 2011 | 1340 | 0.240 |
Why?
| | Molecular Targeted Therapy | 2 | 2017 | 354 | 0.230 |
Why?
| | Neoplasms, Unknown Primary | 1 | 2023 | 12 | 0.220 |
Why?
| | Disease-Free Survival | 3 | 2013 | 634 | 0.210 |
Why?
| | Molecular Diagnostic Techniques | 1 | 2022 | 93 | 0.200 |
Why?
| | Poly (ADP-Ribose) Polymerase-1 | 1 | 2021 | 40 | 0.200 |
Why?
| | Mutation | 3 | 2023 | 3420 | 0.190 |
Why?
| | Computing Methodologies | 1 | 2020 | 2 | 0.190 |
Why?
| | Benzamides | 1 | 2021 | 173 | 0.190 |
Why?
| | Thrombocytosis | 2 | 2014 | 7 | 0.190 |
Why?
| | Survival Analysis | 2 | 2017 | 1240 | 0.190 |
Why?
| | Breast Neoplasms | 2 | 2023 | 1883 | 0.190 |
Why?
| | Genetic Predisposition to Disease | 3 | 2023 | 2227 | 0.180 |
Why?
| | B7-H1 Antigen | 1 | 2021 | 143 | 0.170 |
Why?
| | Immunohistochemistry | 2 | 2017 | 1657 | 0.170 |
Why?
| | Drug Administration Schedule | 1 | 2021 | 723 | 0.170 |
Why?
| | DNA, Neoplasm | 2 | 2011 | 151 | 0.160 |
Why?
| | Antineoplastic Agents, Immunological | 1 | 2020 | 157 | 0.160 |
Why?
| | United States | 3 | 2020 | 12381 | 0.150 |
Why?
| | Carcinoma in Situ | 2 | 2016 | 43 | 0.150 |
Why?
| | Cost-Benefit Analysis | 1 | 2020 | 544 | 0.150 |
Why?
| | Enzyme Multiplied Immunoassay Technique | 1 | 2017 | 2 | 0.150 |
Why?
| | Genetic Counseling | 1 | 2017 | 66 | 0.140 |
Why?
| | Uterine Neoplasms | 2 | 2009 | 73 | 0.140 |
Why?
| | Remission Induction | 1 | 2017 | 243 | 0.140 |
Why?
| | Retrospective Studies | 9 | 2016 | 12825 | 0.140 |
Why?
| | Salpingectomy | 1 | 2016 | 13 | 0.140 |
Why?
| | Drug Resistance, Neoplasm | 1 | 2021 | 668 | 0.140 |
Why?
| | Vaginal Neoplasms | 1 | 2016 | 11 | 0.140 |
Why?
| | Peritoneal Neoplasms | 1 | 2016 | 51 | 0.140 |
Why?
| | Chemotherapy, Adjuvant | 1 | 2016 | 343 | 0.130 |
Why?
| | Case-Control Studies | 2 | 2017 | 3099 | 0.130 |
Why?
| | Medicare | 1 | 2020 | 668 | 0.130 |
Why?
| | Lymph Node Excision | 1 | 2016 | 146 | 0.120 |
Why?
| | Treatment Outcome | 4 | 2021 | 9257 | 0.120 |
Why?
| | Promoter Regions, Genetic | 2 | 2010 | 1141 | 0.120 |
Why?
| | ATP-Binding Cassette Transporters | 1 | 2014 | 124 | 0.110 |
Why?
| | Patient Satisfaction | 1 | 2017 | 595 | 0.110 |
Why?
| | Time Factors | 3 | 2021 | 6240 | 0.110 |
Why?
| | Adenocarcinoma | 2 | 2011 | 794 | 0.110 |
Why?
| | Lymph Nodes | 1 | 2016 | 430 | 0.110 |
Why?
| | Prefrontal Cortex | 1 | 2016 | 264 | 0.110 |
Why?
| | Brain Mapping | 1 | 2016 | 516 | 0.100 |
Why?
| | Terminal Care | 1 | 2015 | 189 | 0.100 |
Why?
| | Health Care Reform | 1 | 2013 | 92 | 0.100 |
Why?
| | Endometrial Hyperplasia | 1 | 2011 | 15 | 0.100 |
Why?
| | Executive Function | 1 | 2016 | 372 | 0.100 |
Why?
| | Progestins | 1 | 2011 | 75 | 0.100 |
Why?
| | Los Angeles | 1 | 2010 | 55 | 0.090 |
Why?
| | MutL Protein Homolog 1 | 1 | 2010 | 10 | 0.090 |
Why?
| | Microsatellite Instability | 1 | 2010 | 32 | 0.090 |
Why?
| | Germ-Line Mutation | 1 | 2010 | 132 | 0.080 |
Why?
| | Clinical Trials as Topic | 1 | 2013 | 957 | 0.080 |
Why?
| | Carcinoma, Papillary | 1 | 2009 | 75 | 0.080 |
Why?
| | Polymerase Chain Reaction | 1 | 2011 | 1001 | 0.080 |
Why?
| | Hysterectomy | 2 | 2007 | 117 | 0.080 |
Why?
| | Cell Line, Tumor | 1 | 2015 | 2814 | 0.080 |
Why?
| | Conization | 1 | 2007 | 1 | 0.080 |
Why?
| | Healthcare Disparities | 1 | 2013 | 494 | 0.070 |
Why?
| | Gynecologic Surgical Procedures | 1 | 2007 | 49 | 0.070 |
Why?
| | Adaptor Proteins, Signal Transducing | 1 | 2010 | 391 | 0.070 |
Why?
| | Fertility | 1 | 2007 | 136 | 0.070 |
Why?
| | Oligonucleotide Array Sequence Analysis | 1 | 2008 | 761 | 0.070 |
Why?
| | Follow-Up Studies | 3 | 2016 | 4507 | 0.070 |
Why?
| | Risk Factors | 3 | 2023 | 8873 | 0.070 |
Why?
| | Incidence | 3 | 2021 | 2377 | 0.070 |
Why?
| | Nuclear Proteins | 1 | 2010 | 591 | 0.060 |
Why?
| | DNA Methylation | 1 | 2010 | 512 | 0.060 |
Why?
| | Membrane Proteins | 1 | 2011 | 1040 | 0.060 |
Why?
| | Uterine Cervical Neoplasms | 1 | 2007 | 214 | 0.060 |
Why?
| | Neoplasm Grading | 2 | 2016 | 247 | 0.060 |
Why?
| | Age Factors | 1 | 2010 | 2951 | 0.060 |
Why?
| | Mass Screening | 1 | 2010 | 1034 | 0.050 |
Why?
| | Algorithms | 1 | 2010 | 1505 | 0.050 |
Why?
| | Cohort Studies | 4 | 2016 | 5051 | 0.050 |
Why?
| | Practice Guidelines as Topic | 1 | 2010 | 1403 | 0.050 |
Why?
| | Young Adult | 2 | 2016 | 10675 | 0.050 |
Why?
| | Mammography | 1 | 2021 | 121 | 0.050 |
Why?
| | California | 1 | 2021 | 366 | 0.050 |
Why?
| | Population Surveillance | 2 | 2013 | 406 | 0.040 |
Why?
| | Early Detection of Cancer | 1 | 2021 | 356 | 0.040 |
Why?
| | Databases, Factual | 1 | 2021 | 1167 | 0.040 |
Why?
| | Anisotropy | 1 | 2016 | 63 | 0.030 |
Why?
| | Heterozygote | 1 | 2016 | 256 | 0.030 |
Why?
| | Disease Progression | 2 | 2016 | 2467 | 0.030 |
Why?
| | Diffusion Magnetic Resonance Imaging | 1 | 2016 | 86 | 0.030 |
Why?
| | Models, Anatomic | 1 | 2016 | 92 | 0.030 |
Why?
| | Factor Analysis, Statistical | 1 | 2016 | 261 | 0.030 |
Why?
| | Lymphatic Metastasis | 1 | 2016 | 286 | 0.030 |
Why?
| | Electronic Health Records | 1 | 2021 | 809 | 0.030 |
Why?
| | Risk Reduction Behavior | 1 | 2016 | 197 | 0.030 |
Why?
| | ATP Binding Cassette Transporter 1 | 1 | 2014 | 10 | 0.030 |
Why?
| | White Matter | 1 | 2016 | 109 | 0.030 |
Why?
| | Memory, Short-Term | 1 | 2016 | 222 | 0.030 |
Why?
| | Real-Time Polymerase Chain Reaction | 1 | 2014 | 331 | 0.030 |
Why?
| | Attention | 1 | 2016 | 390 | 0.030 |
Why?
| | Referral and Consultation | 1 | 2017 | 640 | 0.030 |
Why?
| | Diagnosis, Differential | 1 | 2016 | 1341 | 0.030 |
Why?
| | Hospice Care | 1 | 2015 | 181 | 0.030 |
Why?
| | Advance Care Planning | 1 | 2015 | 193 | 0.030 |
Why?
| | Kaplan-Meier Estimate | 1 | 2014 | 825 | 0.030 |
Why?
| | Health Personnel | 1 | 2017 | 575 | 0.030 |
Why?
| | Neuropsychological Tests | 1 | 2016 | 924 | 0.020 |
Why?
| | Premenopause | 1 | 2011 | 105 | 0.020 |
Why?
| | Predictive Value of Tests | 1 | 2016 | 1825 | 0.020 |
Why?
| | Neoplastic Stem Cells | 1 | 2014 | 335 | 0.020 |
Why?
| | Precancerous Conditions | 1 | 2011 | 156 | 0.020 |
Why?
| | Cell Movement | 1 | 2014 | 877 | 0.020 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2014 | 1159 | 0.020 |
Why?
| | Carboplatin | 1 | 2009 | 140 | 0.020 |
Why?
| | Brachytherapy | 1 | 2009 | 104 | 0.020 |
Why?
| | Paclitaxel | 1 | 2009 | 192 | 0.020 |
Why?
| | Multivariate Analysis | 1 | 2011 | 1458 | 0.020 |
Why?
| | Genome-Wide Association Study | 1 | 2014 | 1314 | 0.020 |
Why?
| | Parity | 1 | 2007 | 101 | 0.020 |
Why?
| | Medical Records | 1 | 2007 | 159 | 0.020 |
Why?
| | RNA, Messenger | 1 | 2014 | 2632 | 0.020 |
Why?
| | Combined Modality Therapy | 1 | 2009 | 1144 | 0.020 |
Why?
| | Surveys and Questionnaires | 1 | 2017 | 4661 | 0.020 |
Why?
| | Pregnancy Outcome | 1 | 2007 | 342 | 0.020 |
Why?
| | Reoperation | 1 | 2007 | 535 | 0.020 |
Why?
| | Emergency Service, Hospital | 1 | 2015 | 1835 | 0.020 |
Why?
| | Proportional Hazards Models | 1 | 2006 | 1105 | 0.010 |
Why?
| | Pregnancy | 1 | 2007 | 5653 | 0.010 |
Why?
| | Male | 1 | 2016 | 56664 | 0.010 |
Why?
|
|
Walsh's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|